Status:
COMPLETED
A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
Lead Sponsor:
UCB Pharma
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects wit...
Detailed Description
See approved Package Insert for Adverse Event information.
Eligibility Criteria
Inclusion
- Stable Parkinson's Disease
Exclusion
- Not using carbidopa/levodopa tablets
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00139867
Start Date
January 1 2004
End Date
May 1 2004
Last Update
October 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Milwaukee, Wisconsin, United States